TCT 2021: Philips announces new innovations and clinical data
supporting the treatment of patients with cardiovascular disease
November 2, 2021
- Philips debuts three new solutions in the North American market
that will help drive procedural innovation and workflow efficiency,
adding to the company’s ecosystem of interventional imaging
systems, and diagnostic and therapeutic devices
- New clinical data presented at TCT 2021: five-year outcomes of
iFR-SWEDEHEART trial and new large-scale analysis of Centers for
Medicare & Medicaid Services (CMS) data on use of Intravascular
Ultrasound (IVUS) in diagnosing and treating peripheral vascular
disease
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today
announced North American availability of new innovations in its
portfolio of cardiology solutions designed to seamlessly work
together, strengthen clinical confidence, build efficiency
throughout the care pathway, and improve cardiac care outcomes and
experiences. The new updates, aimed at innovating and advancing
procedures including percutaneous coronary intervention (PCI) to
treat the narrowing of coronary arteries, are being announced at
the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting
(Orlando, USA, November 4-6). In addition, Philips is putting a
spotlight on new clinical data being presented at TCT that shows
how novel minimally-invasive techniques are helping to innovate
interventional procedures and improve patient outcomes.
The demands on cardiology departments are higher than ever
before, forcing clinicians to balance the delivery of high-quality
care for a growing volume of complex patients with the challenge of
improving departmental efficiency at the same time.
“Interventional physicians seek ever-more precise, accurate and
efficient tools to decide, guide, treat and confirm the right
therapy for the right patient at the point of care,” said Chris
Landon, Senior Vice President and General Manager, Image Guided
Therapy Devices at Philips. “At this year’s TCT, we’re showing how
we are continuously innovating and expanding our integrated
ecosystem of interventional imaging systems and diagnostic and
therapeutic devices to provide clinicians with a complete solution,
from diagnosis to treatment and therapy monitoring, to optimize
their workflow and the treatment of each individual patient.”
North America debut of Philips’ mobile interventional
applications platformThe new Philips Interventional
Applications Platform – IntraSight Mobile – is now available in
North America. IntraSight Mobile brings together imaging and
physiology applications on a mobile system for coronary and
peripheral artery disease therapy. The IntraSight platform allows
interventional cardiologists to perform intravascular ultrasound
(IVUS) imaging and physiologic measurements of fractional flow
reserve (FFR) and instant wave-free ratio (iFR) to accurately
identify the location of lesions causing ischemia.
IntraSight Mobile builds on the success of Philips
Interventional Applications Platform – IntraSight – a solution that
integrates intravascular diagnostic applications into a smart,
simple and seamless workflow solution for interventional labs.
IntraSight Mobile is compatible with Philips’ current and future
portfolio of imaging and physiology modalities. The system includes
a touchscreen panel PC and a ruggedized, multi-modality touchscreen
module mounted on a modern and easy to maneuver mobile cart for all
environments. IntraSight Mobile offers clinicians an intuitive user
interface and simplified workflow, enhancing the user experience
while optimizing lab performance. Clinicians can customize the
platform and select best-in-class tools that are right for their
coronary or peripheral vascular patients.
Superior deliverability with new scoring
balloonThe newly designed Philips Scoring Balloon Catheter
RX – AngioSculpt Evo – has superior deliverability and the power to
safely dilate resistant lesions [1, 2, 3]. It comes with a
combination of changes, including a smaller tip for smoother lesion
entry, a hydrophilic coating to reduce friction, and a laser-cut
hypotube for enhanced flexibility. The helical nitinol scoring
elements wrap the balloon around its circumference to minimize
slippage and lock to the lesion, delivering up to 25 times [1] the
force of a non-compliant balloon. This device is available for
treatment of coronary artery stenosis, including in-stent
restenosis.
Introduction of new laser systemThe new Philips
Laser System – Nexcimer – offers plug-and-play simplicity for
coronary and peripheral atherectomy and lead extraction
procedures. Smaller, lighter, and more maneuverable than the
previous generation [4], the system starts up within 30 seconds,
uses standard medical-grade 100-240V outlets, and has an intuitive
touchscreen interface with guided workflow prompts that help lessen
the need for technician training. It is the only system compatible
with catheters with Level I clinical data for ISR atherectomy and
that can also support lead extraction procedures (the removal of
pacemaker or defibrillator leads around the heart) [5, 6].
An innovative cardiology experience with Philips at TCT
2021Visitors to TCT 2021 will have access to Philips’
latest solutions, plus opportunities to engage with clinical
experts and experience innovative cardiac solutions. Philips’
technology advancements in diagnostic, interventional and
monitoring solutions at TCT 2021 include:
- New real-time Philips 3D Intracardiac Echocardiography
Catheter – VeriSight Pro: The new VeriSightPro used with
Philips’ EPIQ CVx and CVxi Premium Ultrasound Systems offers
superior 2D and 3D live image guidance for a wide range of
procedures in structural heart disease and electrophysiology.
- Advanced ultrasound solutions to set the standard of
care for interventional cardiology: Philips Ultrasound
System – EPIQ CVxi – is an advanced ultrasound solution that can
help clinicians deliver improved care through exceptional image
quality, robust quantification, and Echo Navigator live fusion
imaging.
- Advancing clinical and operational lab performance
with Philips Image-Guided Therapy System
–Azurion: Intuitive, integrated, and
efficient, the next-generation Azurion is an advanced image-guided
therapy platform that supports providers to perform procedures
easily and confidently with a unique user experience.
- Advanced mobile outpatient cardiac monitoring:
Philips cardiac care solutions and BioTelemetry’s leading remote
cardiac patient monitoring have transformed the cardiac care
pathway. This platform integrates data from almost any remote
cardiac monitoring device with analysis and support to streamline
workflow in clinical practices.
New clinical data presented at TCT 2021
Five-year outcomes of the iFR-SWEDEHEART trial:
On Thursday, November 4, at 1:45pm EST/7:45pm CET, as part of TCT’s
Late-Breaking Clinical Trials and Science program, five-year
outcomes of the iFR-SWEDEHEART trial will be presented by Matthias
Götberg, MD, PhD, interventional cardiologist and Director of the
Cardiac Catheterization Lab at Skane University Hospital, Lund,
Sweden. Join to hear the data results: iFR-SWEDEHEART: Five-Year
Outcomes of a Randomized Trial of iFR-Guided vs. FFR-Guided PC.
Large-scale study outcomes on use of IVUS: On
Saturday, November 6, at 2:24pm EST/8:24pm CET, Eric A. Secemsky,
MD, Interventional Cardiologist at Beth Israel Deaconess Medical
Center and Assistant Professor of Medicine at Harvard Medical
School in Boston, MA, will present a new large-scale analysis of
Centers for Medicare & Medicaid Services (CMS) data on the
clinical and economic outcomes of diagnosing and treating
peripheral vascular disease using intravascular ultrasound (IVUS).
Learn more here about his TCT Innovation Theater session titled:
Endovascular Featured Clinical Research – Utilization of
Intravascular Ultrasound During Peripheral Venous Intervention
Among Medicare Beneficiaries.
Philips hosted webinars, symposium, and virtual
cardiology experience As the patient population increases
in age so does the presentation of high-risk individuals with
multiple co-morbidities. On Thursday, November 4, at 4:00pm
EST/10:00pm CET, tune in live at TCT to hear from Dr. Ziad A. Ali,
Dr. Allen Jeremias, and Dr. Karim Al-Azizi on how they perform
ultra-low contrast PCI to treat their high-risk patients and learn
what tools and techniques they adopt to optimize patient
outcomes.
For the full calendar of events, as well as general information
about Philips’ presence at the show, visit www.philips.com/TCT.
Visit the Philips Industry Hub to experience innovative cardiac
solutions and follow the #TCT2021 conversation on @PhilipsLiveFrom
throughout the event.
Refer to full Philips Laser System device labeling and
instructions for important safety information. Caution: Federal law
restricts this device to sale by or on the order of a
physician.
[1] D051336 AngioSculpt Evo Marketing Claims Report. Internal
AngioSculpt Test Report SR-1571.A (2008).[2] Costa RA, Mooney
MR, Teirstein PS, et al. Final results from the multi-center trial
of the angiosculpt scoring balloon catheter for the treatment of
complex coronary artery lesions Cardiovascular Revascularization
Medicine 7 (2006)81–126.[3] Costa JR, Mintz GS, Carlier SG, et al.
Nonrandomized comparison of coronary stenting under intravascular
ultrasound guidance of direct stenting without predilation versus
conventional predilation with a semi-compliant balloon versus
predilation with a new scoring balloon. Am J Cardiol.
2007;100:812-817. [4] Comparison to previous generation
(CVX-300).[5] Philips Laser System Data Sheet Specifications.[6]
Dippel et al. Randomized Controlled Study of Excimer Laser
Atherectomy for Treatment of Femoropopliteal In-stent Restenosis:
Initial ISR Results (2015). JACC 8(1): 92-101.[7] Gotberg M, et
al., iFR-SWEDEHEART Investigators. Instantaneous Wave-free Ratio
versus Fractional Flow Reserve to Guide PCI. N Engl J Med. 2017 May
11;376(19):1813-18233.
For further information, please contact:
Joost MalthaPhilips Global Press OfficeTel.: +31 610
558116E-mail: joost.maltha@philips.com
Fabienne van der FeerPhilips Image Guided TherapyTel: + 31 622
698 001E-mail : fabienne.van.der.feer@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
well-being, and enabling better outcomes across the health
continuum – from healthy living and prevention, to diagnosis,
treatment and home care. Philips leverages advanced technology and
deep clinical and consumer insights to deliver integrated
solutions. Headquartered in the Netherlands, the company is a
leader in diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as in consumer health
and home care. Philips generated 2020 sales of EUR 17.3 billion and
employs approximately 78,000 employees with sales and services in
more than 100 countries. News about Philips can be found at
www.philips.com/newscenter.
- Philips Interventional Applications Platform – IntraSight
Mobile
- Philips Laser System – Nexcimer
- Philips Scoring Balloon Catheter RX – AngioSculpt Evo
- Philips Image Guided Therapy System – Azurion
Koninklijke Philips NV (EU:PHIA)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Koninklijke Philips NV (EU:PHIA)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024